Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma

References

• Morgan G, Vornanen M, Puitinen J, et al. Changing trends in the incidence of non-Hodgkin’s lymphoma in Europe. Biomed study group. Ann Oncol Off J Eur Soc Med Oncol ESMO. 1997;8(Suppl 2):S49–S54.
   Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jun 20;346(25):1937–1947.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003 Sep 15;198(6):851–862.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000 Feb 3;403(6769):503–511.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) group. Lancet Oncol. 2006 May;7(5):379–391.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol Off J Am Soc Clin Oncol. 2005 Jun 20;23(18):4117–4126.
   PubMed Web of Science ®Google Scholar
• Tilly H, Gomes Da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2015 Sep;26(Suppl 5):v116v125.
   Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010 Sep 23;116(12):2040–2045.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2006 Jul 1;24(19):3121–3127.
   PubMed Web of Science ®Google Scholar
• Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet Lond Engl. 2011 Nov 26;378(9806):1858–1867.
   PubMed Web of Science ®Google Scholar
• Stiff PJ, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive Non-Hodgkin’s Lymphoma. N Engl J Med. 2013 Oct 31;369(18):1681–1690.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Chiappella A, Angelucci E, et al. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica. 2009 Sep;94(9):1250–1258.
   PubMed Web of Science ®Google Scholar
• Dilhuydy M-S, Lamy T, Foussard C, et al. Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a phase II GOELAMS study. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2010 May;16(5):672–677.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012 Dec;13(12):1250–1259.
   PubMed Web of Science ®Google Scholar
• Ziepert M, Hasenclever D, Kuhnt E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol Off J Am Soc Clin Oncol. 2010 May 10;28(14):2373–2380.
   PubMed Web of Science ®Google Scholar
• Vaidya R, Witzig TE. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2014 Nov;25(11):2124–2133.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004 Jan 1;103(1):275–282.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009 Oct 22;114(17):3533–3537.
   PubMed Web of Science ®Google Scholar
• Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol Off J Am Soc Clin Oncol. 2010 Jul 10;28(20):3360–3365.
   PubMed Web of Science ®Google Scholar
• Klapper W, Stoecklein H, Zeynalova S, et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German high-grade Non-Hodgkin’s Lymphoma study group (DSHNHL). Leukemia. 2008 Dec;22(12):2226–2229.
   PubMed Web of Science ®Google Scholar
• Mø P, Gang AO, Poulsen TS, et al. Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre’s experience. Eur J Haematol. 2012 Jul;89(1):63–71.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Tsutsumi Y, Sakamoto N, et al. Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab. Jpn J Clin Oncol. 2012 Nov;42(11):1035–1042.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Traverse-Glehen A, Coiffier B. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas. Lancet Oncol. 2015 Nov;16(15):e555–567.
   PubMedGoogle Scholar
• Alinari L, Gru A, Quinion C, et al. De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol. 2016 Jun;91(4):395–399.
   PubMed Web of Science ®Google Scholar
• Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014 Jan;11(1):12–23.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Coiffier B. Primary refractory diffuse large B cell lymphoma in the rituximab era. Curr Opin Oncol. 2015 Sep;27(5):377–383.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet Lond Engl. 2013 May 25;381(9880):1817–1826.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007 Mar 1;109(5):1857–1861.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bartlett NL, Vose JM, et al. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer. 2012 Jun 15;118(12):3128–3134.
   PubMed Web of Science ®Google Scholar
• Gyan E, Damotte D, Courby S, et al. High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. Br J Haematol. 2013 juillet;162(2):240–249.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Schmitz N, Mounier N, et al. Diffuse Large B-Cell Lymphoma (DLBCL) patients failing second-line R-DHAP Or R-ICE chemotherapy included in the coral study. Blood. 2013 Nov 15;122(21):764–764.
   Google Scholar
• Jerkeman M, Dictor M, Kval�y S, et al. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma?a nordic lymphoma group study. Ann Hematol. 2004 Jul 1;83(7):414–419.
   PubMed Web of Science ®Google Scholar
• Kahl BS, Bailey HH, Smith EP, et al. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin’s lymphoma: a Wisconsin oncology network study. Cancer Invest. 2005;23(1):13–18.
   PubMed Web of Science ®Google Scholar
• Gutierrez M, Chabner BA, Pearson D, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol Off J Am Soc Clin Oncol. 2000 Nov 1;18(21):3633–3642.
   PubMed Web of Science ®Google Scholar
• Martín A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica. 2008 Dec;93(12):1829–1836.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995 Dec 7;333(23):1540–1545.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the Rituximab Era. J Clin Oncol. 2010 Sep 20;28(27):4184–4190.
   PubMed Web of Science ®Google Scholar
• Hamadani M, Hari PN, Zhang Y, et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Nov;20(11):1729–1736.
   PubMed Web of Science ®Google Scholar
• Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): results from the international SCHOLAR-1 study. J Clin Oncol. cited 2016 Jul 27. Available from: http://meetinglibrary.asco.org/content/168908-176
   Web of Science ®Google Scholar
• Cuccuini W, Briere J, Mounier N, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood. 2012 May 17;119(20):4619–4624.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol Off J Am Soc Clin Oncol. 2011 Nov 1;29(31):4079–4087.
   PubMed Web of Science ®Google Scholar
• Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol Off J Am Soc Clin Oncol. 2014 Nov 1;32(31):3490–3496.
   PubMed Web of Science ®Google Scholar
• Lignon J, Sibon D, Madelaine I, et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):262–269.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 1999 Dec;17(12):3776–3785.
   PubMed Web of Science ®Google Scholar
• Prince HM, Crump M, Imrie K, et al. Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma. Ann Oncol Off J Eur Soc Med Oncol ESMO. 1996 Dec;7(10):1043–1049.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Fanti S, Battista G, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer. 2004 Aug 31;91(5):850–854.
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Moskowitz CH, Zhang Z, et al. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplant. 2009 Jan 12;43(12):941–948.
   PubMed Web of Science ®Google Scholar
• Sauter CS, Matasar MJ, Meikle J, et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015 Apr 16;125(16):2579–2581.
   PubMed Web of Science ®Google Scholar
• Mills W, Chopra R, McMillan A, et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 1995 Mar;13(3):588–595.
   PubMed Web of Science ®Google Scholar
• Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant. 1997 Sep;20(6):451–458.
   PubMed Web of Science ®Google Scholar
• Wang EH, Chen YA, Corringham S, et al. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant. 2004 Oct;34(7):581–587.
   PubMed Web of Science ®Google Scholar
• Decaudin D, Mounier N, Tilly H, et al. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):212–218.
   PubMed Web of Science ®Google Scholar
• Auger-Quittet S, Duny Y, Daures J-P QP. Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis. Cancer Med. 2014 Aug;3(4):927–938.
   PubMed Web of Science ®Google Scholar
• Shimoni A, Avivi I, Rowe JM, et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012 Oct 1;118(19):4706–4714.
   PubMed Web of Science ®Google Scholar
• Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011 Sep 22;118(12):3419–3425.
   PubMed Web of Science ®Google Scholar
• Garciaz S, Coso D, Schiano De Collela J-M, et al. Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity. Bone Marrow Transplant. 2016 Feb;51(2):319–321.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2012 Dec 20;30(36):4462–4469.
   PubMed Web of Science ®Google Scholar
• Biswas T, Dhakal S, Chen R, et al. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):79–85.
   PubMed Web of Science ®Google Scholar
• Oehler-Jänne C, Taverna C, Stanek N, et al. Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin’s lymphoma: a case-control study. Hematol Oncol. 2008 Jun;26(2):82–90.
   PubMed Web of Science ®Google Scholar
• Toren A, Nagler R, Nagler A. Involved field radiation post autologous stem cell transplantation in lymphoma patients is associated with major haematological toxicities. Med Oncol Northwood Lond Engl. 1998 Jul;15(2):113–118.
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016 Jan;51(1):51–57.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS. Participation in clinical trials to improve outcomes of patients with relapsed lymphoma. 2016 ASCO Annu Meet. AbstractNumber 7523.
   Google Scholar
• Lazarus HM, Zhang M-J, Carreras J, et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2010 Jan;16(1):35–45.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Boumendil A, Finel H, et al. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma working party. Bone Marrow Transplant. 2016 Mar;51(3):365–371.
   PubMed Web of Science ®Google Scholar
• Nagle SJ, Woo K, Schuster SJ, et al. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am J Hematol. 2013 Oct;88(10):890–894.
   PubMed Web of Science ®Google Scholar
• Rjw VK, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European group for blood and marrow transplantation registry. J Clin Oncol Off J Am Soc Clin Oncol. 2011 Apr 1;29(10):1342–1348.
   PubMed Web of Science ®Google Scholar
• Sirvent A, Dhedin N, Michallet M, et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the societe Française de greffe de moelle et de therapie cellulaire. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2010 Jan;16(1):78–85.
   PubMed Web of Science ®Google Scholar
• Glass B, Hasenkamp J, Wulf G, et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol. 2014 Jun;15(7):757–766.
   PubMed Web of Science ®Google Scholar
• Fenske TS, Ahn KW, Graff TM, et al. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016 Jul;174(2):235–248.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008 Feb;9(2):105–116.
   PubMed Web of Science ®Google Scholar
• Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol. 2013 May;14(6):525–533.
   PubMed Web of Science ®Google Scholar
• Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011 May;12(5):460–468.
   PubMed Web of Science ®Google Scholar
• Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II lymphoma study association trial. Haematologica. 2013 Nov;98(11):1726–1731.
   PubMed Web of Science ®Google Scholar
• Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2013 Jun 10;31(17):2103–2109.
   PubMed Web of Science ®Google Scholar
• Arcari A, Chiappella A, Spina M, et al. Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. Leuk Lymphoma. 2016 Aug;57(8):1823–1830.
   PubMed Web of Science ®Google Scholar
• Merchionne F, Quintana G, Gaudio F, et al. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis. Leuk Res. 2014 Dec;38(12):1446–1450.
   PubMed Web of Science ®Google Scholar
• Sarid N, Joffe E, Gibstein L, et al. Reduced-dose ICE chemotherapy ± rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016 Jul;57(7):1633–1639.
   PubMed Web of Science ®Google Scholar
• Arnason JE, Luptakova K, Rosenblatt J, et al. Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant. Acta Haematol. 2015;133(4):347–353.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Radford J, Bosly A, et al. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Br J Haematol. 2013 Nov 1;163(3):334–342.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Pellegrini C, Derenzini E, et al. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. Hematol Oncol. 2013 décembre;31(4):223–224.
   PubMed Web of Science ®Google Scholar
• Mondello P, Steiner N, Willenbacher W, et al. Lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: is it a valid treatment option? Oncologist. 2016 Sep;21(9):1107–1112.
   PubMed Web of Science ®Google Scholar
• Fang C, Zhu D, Dong H, et al. Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8(7):10705–10713.
   PubMed Web of Science ®Google Scholar
• Yang Y, Shaffer AL, Emre NCT, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012 Jun 12;21(6):723–737.
   PubMed Web of Science ®Google Scholar
• Zhang L-H, Kosek J, Wang M, et al. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol. 2013 Feb;160(4):487–502.
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol Off J Am Soc Clin Oncol. 2013 Jan 1;31(1):88–94.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015 Aug;21(8):922–926.
   PubMed Web of Science ®Google Scholar
• Bu R, Hussain AR, Kas A-O, et al. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma. Leuk Lymphoma. 2014 Feb;55(2):415–424.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009 Jun 11;113(24):6069–6076.
   PubMed Web of Science ®Google Scholar
• Bradley WD, Arora S, Busby J, et al. EZH2 inhibitor efficacy in non-Hodgkin’s lymphoma does not require suppression of H3K27 monomethylation. Chem Biol. 2014 Nov 20;21(11):1463–1475.
   PubMedGoogle Scholar
• Li L, Pongtornpipat P, Tiutan T, et al. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia. 2015 Aug;29(8):1702–1712.
   PubMed Web of Science ®Google Scholar
• Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. Clin Adv Hematol Oncol. 2014 Aug;12(8 Suppl 16):18–9.
   Google Scholar
• Chaidos A, Caputo V, Karadimitris A. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Ther Adv Hematol. 2015 Jun;6(3):128–141.
   PubMed Web of Science ®Google Scholar
• Pfeifer M, Zheng B, Erdmann T, et al. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia. 2015 Jul;29(7):1578–1586.
   PubMed Web of Science ®Google Scholar
• Mca P-W, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015 Jun;16(6):704–715.
   PubMed Web of Science ®Google Scholar
• Goebeler M-E, Knop S, Viardot A, et al. Bispecific T-Cell Engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma: final results from a phase I study. J Clin Oncol Off J Am Soc Clin Oncol. 2016 Apr 1;34(10):1104–1111.
   PubMed Web of Science ®Google Scholar
• Viardot A, Goebeler M-E, Hess G, et al. Phase 2 study of bispecific T-cell engager (BiTE®) antibody blinatumomab in relapsed/refractory diffuse large B cell lymphoma. Blood. 2016 Mar 17;127(11):1410–1416.
   PubMed Web of Science ®Google Scholar
• Tsiatas M, Mountzios G, Curigliano G. Future perspectives in cancer immunotherapy. Ann Transl Med. 2016 Jul;4(14):273.
   PubMed Web of Science ®Google Scholar
• Witkowska M, Smolewski P, Majchrzak A, et al. Innovation in non-Hodgkin lymphoma drug discovery: what needs to be done? Expert Opin Drug Discov. 2016 Aug 27;11:1033–1045.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol Off J Am Soc Clin Oncol. 2016 Aug 10;34(23):2698–2704.
   PubMed Web of Science ®Google Scholar
• Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic Anti–PD-L1 monoclonal antibody. Cancer Immunol Res. 2015 Sep 1;3(9):1052–1062.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-Cell lymphoma and indolent B-Cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015 Feb 20;33(6):540–549.
   PubMed Web of Science ®Google Scholar